title: Analysis of the selective advantage conferred by a C-E1 fusion protein synthesized by rubella virus DI RNAs.
abstract: During serial passaging of rubella virus (RUB) in cell culture, the dominant species of defective-interfering RNA (DI) generated contains an in-frame deletion between the capsid protein (C) gene and E1 glycoprotein gene resulting in production of a C-E1 fusion protein that is necessary for the maintenance of the DI [Tzeng, W.P., Frey, T.K. (2006). C-E1 fusion protein synthesized by rubella virus DI RNAs maintained during serial passage. Virology 356 198-207.]. A BHK cell line stably expressing the RUB structural proteins was established which was used to package DIs into virus particles following transfection with in vitro transcripts from DI infectious cDNA constructs. Packaging of a DI encoding an in-frame C-GFP-E1 reporter fusion protein corresponding to the C-E1 fusion protein expressed in a native DI was only marginally more efficient than packaging of a DI encoding GFP, indicating that the C-E1 fusion protein did not function by enhancing packaging. However, infection with the DI encoding the C-GFP-E1 fusion protein (in the absence of wt RUB helper virus) resulted in formation of clusters of GFP-positive cells and the percentage of GFP-positive cells in the culture following infection remained relatively constant. In contrast, a DI encoding GFP did not form GFP-positive clusters and the percentage of GFP-positive cells declined by roughly half from 2 to 4 days post-infection. Cluster formation and sustaining the percentage of infected (GFP-positive) cells required the C part of the fusion protein, including the downstream but not the upstream of two arginine clusters (both of which are associated with RNA binding and association with mitochondrial p32 protein) and the E1 part through the transmembrane sequence, but not the C-terminal cytoplasmic tail. Among a collection of mutant DI constructs, cluster formation and sustaining infected cell percentage correlated with maintenance during serial passage with wt RUB. We hypothesize that cluster formation and sustaining infected cell percentage increase the likelihood of co-infection by a DI and wt RUB during serial passage thus enhancing maintenance of the DI. Cluster formation and sustaining infected cell percentage were found to be due to a combination of attenuated cytopathogenicity of DIs that express the C-E1 fusion protein and cell-to-cell movement of the DI. In infected cells, the C-GFP-E1 fusion protein was localized to potentially novel vesicular structures that appear to originate from ER-Golgi transport vacuoles. This species of DI expressing a C-E1 fusion protein that exhibits attenuated cytopathogenicity and the ability to increase the number of infected cells through cell-to-cell movement could be the basis for development of an attractive vaccine vector.
authors: Institute of Virology, University of Leipzig, Leipzig, Germany.
authors: Claudia
authors: C
authors: Claus
authors: Wen-Pin
authors: WP
authors: Tzeng
authors: Uwe Gerd
authors: UG
authors: Liebert
authors: Teryl K
authors: TK
authors: Frey
mesh_terms: D000818:Animals; D002460:Cell Line; D006224:Cricetinae; D003588:Cytopathogenic Effect, Viral; D003673:Defective Viruses / Q000235:genetics / Q000254:growth & development* / Q000472:pathogenicity; D050939:Gene Fusion / Q000235:genetics / Q000502:physiology*; D017930:Genes, Reporter; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D050506:Mutant Chimeric Proteins / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D012412:Rubella virus / Q000254:growth & development* / Q000472:pathogenicity; D012692:Serial Passage; D022161:Transport Vesicles / Q000737:chemistry; D014758:Viral Core Proteins / Q000235:genetics / Q000502:physiology*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000502:physiology*; D015678:Viral Structural Proteins / Q000032:analysis / Q000235:genetics / Q000502:physiology; D019065:Virus Assembly / Q000235:genetics / Q000502:physiology
chemical_list: D050506:Mutant Chimeric Proteins; D011993:Recombinant Fusion Proteins; D014758:Viral Core Proteins; D014759:Viral Envelope Proteins; D015678:Viral Structural Proteins; C074573:nucleocapsid protein (C), rubella virus; C061826:E1 envelope protein, Rubella virus; D049452:Green Fluorescent Proteins
references: J Virol. 2003 Sep;77(17):9502-10
references: 12915564
references: Virology. 2005 Jul 5;337(2):327-34
references: 15907967
references: Cell Biol Int. 2003;27(9):711-7
references: 12972275
references: J Virol. 2004 Mar;78(5):2553-61
references: 14963158
references: Arch Virol. 2004 Apr;149(4):779-89
references: 15045564
references: Science. 1967 May 5;156(3775):659-61
references: 6023662
references: J Virol. 1970 Apr;5(4):478-89
references: 5465639
references: Intervirology. 1977;8(2):100-9
references: 558175
references: J Clin Invest. 1986 May;77(5):1613-21
references: 3009547
references: Virology. 1988 May;164(1):22-9
references: 3363865
references: Virology. 1991 Jan;180(1):400-5
references: 1984659
references: Virology. 1991 Dec;185(2):811-9
references: 1962452
references: J Cell Biol. 1992 Aug;118(4):795-811
references: 1500424
references: Virology. 1994 Aug 1;202(2):574-85
references: 8030223
references: Adv Virus Res. 1994;44:69-160
references: 7817880
references: Virology. 1995 Jan 10;206(1):216-26
references: 7831776
references: Mol Biol Cell. 1995 Jan;6(1):7-20
references: 7749196
references: Photochem Photobiol. 1995 Oct;62(4):651-6
references: 7480149
references: J Virol. 1996 Apr;70(4):2184-90
references: 8642641
references: J Submicrosc Cytol Pathol. 1996 Jan;28(1):101-8
references: 8929632
references: J Virol. 1997 Jan;71(1):562-8
references: 8985384
references: J Virol. 1997 Oct;71(10):7670-80
references: 9311850
references: Virology. 1998 Jan 5;240(1):57-63
references: 9448689
references: Mol Biol Cell. 1998 Jun;9(6):1265-78
references: 9614173
references: Virology. 1998 Oct 25;250(2):359-70
references: 9792846
references: Virology. 1999 Jun 20;259(1):74-84
references: 10364491
references: J Virol. 1999 Sep;73(9):7805-11
references: 10438871
references: J Gene Med. 2005 Jul;7(7):898-907
references: 15759279
references: J Virol. 2005 Aug;79(16):10807-20
references: 16051872
references: J Physiol. 2005 Oct 15;568(Pt 2):459-68
references: 16037090
references: Arch Virol. 2006 Feb;151(2):327-46
references: 16172842
references: Virology. 2006 Dec 5-20;356(1-2):198-207
references: 16938325
references: Cell Microbiol. 2007 Apr;9(4):875-90
references: 17087733
references: J Virol. 2000 Jun;74(12):5569-76
references: 10823864
references: J Virol. 2000 Nov;74(22):10811-5
references: 11044128
references: Cytometry. 2001 May 1;44(1):57-64
references: 11309809
references: Virology. 2001 Oct 10;289(1):63-73
references: 11601918
references: J Virol. 2003 Feb;77(3):1764-71
references: 12525610
references: Biochem Biophys Res Commun. 2003 May 9;304(3):575-81
references: 12729592
references: Mol Ther. 2003 Jul;8(1):13-20
references: 12842424
references: Biochemistry. 2003 Aug 5;42(30):9185-94
references: 12885253
references: Int J Mol Med. 2005 Jun;15(6):999-1003
references: 15870906
references: Virology. 2003 Aug 1;312(2):261-9
references: 12919732